Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139771 | 0.93 | HSD17B10 (0.73) | HSD17B10ALOX15TSHRKDM4ELMNA | |
| SCHEMBL9611074 | 0.88 | GAA (0.55) | HSD17B10ALOX15TSHRLMNAALDH1A1 | |
| SCHEMBL10246549 | 0.84 | GAA (0.57) | HSD17B10ALOX15TSHRKDM4ELMNA | |
| SCHEMBL18997679 | 0.83 | GAA (0.60) | HSD17B10ALOX15TSHRKDM4ELMNA | |
| SCHEMBL26981196 | 0.82 | HSD17B10 (0.91) | HSD17B10ALOX15TSHRKDM4ELMNA | |
| SCHEMBL25074354 | 0.81 | GAA (0.48) | HSD17B10ALOX15TSHRLMNAALDH1A1 | |
| SCHEMBL12139764 | 0.81 | GAA (0.48) | HSD17B10ALOX15TSHRLMNAALDH1A1 | |
| SCHEMBL12139766 | 0.81 | GAA (0.48) | HSD17B10ALOX15TSHRKDM4EALDH1A1 | |
| SCHEMBL4969885 | 0.81 | HSD17B10 (0.69) | HSD17B10ALOX15TSHRKDM4ELMNA | |
| SCHEMBL14218697 | 0.81 | TSHR (0.69) | HSD17B10ALOX15TSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-02-04 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | HSD17B10 3860/4885ALOX15 2447/4885TSHR 608/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | HSD17B10 3860/4885ALOX15 2447/4885TSHR 608/4885 |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | HSD17B10 1639/4885ALOX15 1818/4885TSHR 4039/4885 |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | HSD17B10 3330/4885ALOX15 2960/4885TSHR 719/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | HSD17B10 1971/4885ALOX15 2274/4885TSHR 3524/4885 |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | RNASE1, HAVCR2, RNASEH1 | HSD17B10 1717/4885ALOX15 2000/4885TSHR 3579/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | HSD17B10 3886/4885ALOX15 3653/4885TSHR 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.